Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prednisone + tacrolimus + mycophenolate mofetil
- Development stage
- Unknown
- Lead developer
- Xi'an Jiaotong University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Prednisone + tacrolimus + mycophenolate mofetil is a triple immunosuppressive regimen investigated for the treatment of focal segmental glomerulosclerosis (FSGS). This combination therapy utilizes three distinct mechanisms to suppress the immune response: prednisone acts as a broad-spectrum corticosteroid to reduce inflammation; tacrolimus (FK506) is a calcineurin inhibitor that prevents T-cell activation; and mycophenolate mofetil (MMF) is an inosine monophosphate dehydrogenase (IMPDH) inhibitor that blocks lymphocyte proliferation. The regimen was notably evaluated in a clinical trial (NCT00956059) by Xi'an Jiaotong University to determine if a low-dose prednisone approach combined with MMF and tacrolimus could provide comparable efficacy with improved safety compared to standard-dose prednisone monotherapy in FSGS patients.
- Other names
- prednisone + FK506 + mycophenolate mofetillow-dose prednisone + MMF + FK506prednisone + tacrolimus + MMF
02
Targets
FKBP1ACN (Calcineurin)GR (Glucocorticoid receptor)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on prednisone + tacrolimus + mycophenolate mofetil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prednisone + tacrolimus + mycophenolate mofetil.